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Abstract
Background: Little is known about the epidemiological characteristics of papillomavirus (HPV) infection among
North African countries. Herein, we conducted a molecular epidemiological study to investigate prevalence of HPV
type and HPV-16 variants among cervical-screened unvaccinated Tunisian women.
Methods: Cross-sectional study was performed on 494 Tunisian women visiting Women’s Healthcare Centers. HPV-DNA
detection was carried out on cervical samples using real-time polymerase chain reaction. HPV genotyping and HPV-16
variants were characterized by direct sequencing of L1 viral capsid gene.
Results: The overall HPV prevalence was 34% (95% CI: 30–38%) with significantly higher prevalence among women with
squamous intraepithelial lesions (SIL) than those with no intraepithelial lesions (NIL) 84% (95% CI: 76–92%)
and 24.5% (95% CI: 20–29%) respectively. The distribution of HPV prevalence according to women’s age shows a
U-shaped curve and the highest HPV prevalence rates were observed among the youngest (≤25 years; 51.2%, 95%
CI: 37–67%) and the oldest women (>55 years; 41.7%, 95% The HPV-16 prevalence was 32.8% (95% CI: 22–45%) among
women with SIL and 9.2% (95% CI: 6–12%) among women with NIL. Whereas, the HPV-18 prevalence was 1.3% (95%
CI: 0–5%) among women with SIL and 0.3% (95% CI: 0–1%) among women with NIL. Among HPV-16 positive women,
European lineage (E) was identified as the predominant HPV-16 variant (85.7%, 95% CI: 76–95%). The frequency of E
variant was lower among SIL than among NIL women (81%, 95% CI: 64–99%, and 88%, 95% CI: 77–100%, respectively).
Conversely, the African-2 variant frequency was higher among SIL than among NIL women (18%, 95% CI: 1–36% and
6%, 95% CI: 2–14%, respectively). In multivariate analysis, young age was the only risk factor that is independently
associated with HPV infection. Moreover, HPV infection and menopause were both found to be independently
associated with SIL and HSIL.
Conclusion: HPV DNA testing should be proposed to young and menopausal Tunisian women. Considering HPV
prevalence, only 13% of the Tunisian women could be protected by the bivalent HPV vaccine. These results may be
helpful for designing an adapted HPV testing and vaccination program in Tunisia.
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Background
According to the International Agency for Research on
Cancer (IARC) 528,000 new cases of cervical cancer
were estimated worldwide in 2012 [1]. In Tunisia, where
Human Papillomavirus (HPV) screening and vaccination
against HPV infection are not common, cervical cancer
represents a major public health problem, with an esti-
mated 265 new diagnosed cancer cases and 103 deaths
in 2012 [1]. Several clinical and molecular epidemio-
logical studies demonstrated that both HPV infection
and persistent infection with high-risk HPV (HR-HPV)
are the leading cause for the progression to cervical
lesions [2, 3]. Papillomavirus are small, non-enveloped
viruses that belong to the Papillomaviridae family with
approximately 8 Kbp circular double-stranded DNA.
The genome encodes for 6 early proteins responsible for
virus replication and 2 late proteins L1 and L2, which
are the viral structural proteins [4, 5]. According to De
Villiers et al, determination of HPV types, subtypes and
variants are based on L1 gene sequence similarities [6].
To date, more than 200 different HPV genotypes have
been identified [7], of which 30 to 40 infect the genital
tract through sexual contact and are classified on the
basis of their oncogenic potential as HR-HPV and low-
risk HPV (LR-HPV) [8, 9]. The most frequent HR types,
HPV-16 and -18, are associated with approximately 70%
of cervical cancer cases worldwide [10]. HPV-16 variants
have been well characterized and can be divided into 4
phylogenetic variants: European (E), Asian-American
(AA), African-1 (Af-1) and African-2 (Af-2) [11]. Several
reports have described that HPV-16 variants differ in
their pathogenicity and can affect the persistence of
HPV infection and its progression from cervical precan-
cerous lesion to cervical cancer. For instance, HPV-16
non-European variants were more pathogenic in high-
grade cervical lesions than European variants [12, 13].
The age specific HPV prevalence has varied widely
across different population and showed a bimodal distri-
bution with two peaks of HPV positivity in younger and
older women, respectively [14–16]. In addition, a meta-
analysis including 78 studies reported that, in Africa,
Europe and America, a clear second peak of HPV infec-
tion was observed in women older than 45 years [17].
As HPV infection is sexually transmitted, the HPV-
associated cervical lesions are associated with several
sexual habits and a particular lifestyle, such as younger
age at first sexual intercourse, multi-sexual partners,
smoking and oral contraceptive use [18, 19].
So far, few molecular epidemiological studies on
HPV infections have been conducted in North-African
countries, which is a region located at a crossroad of
Southern Europe, Sub-Saharan Africa and the broader
Middle East [20–22]. This location allows meeting,
crossing and interaction of the different Mediterranean
civilizations that had lived in North Africa along several
centuries (Berber, Arabo-Islamic, Ottoman and European).
Therefore, the current North-African social and cultural
habits are a mixture of influences from these very different
cultures that may give a peculiar profile of risk factors to
HPV infection and cervical lesions.
The present study aimed to investigate HPV preva-
lence, HPV genotype and HPV-16 variants distribution
among women attending Women’s Healthcare Centers
in the central region of Tunisia. This study would pro-
vide background information to improve cervical cancer
screening and to predict the impact of HPV vaccination
program in an Arab Muslim country.
Methods
Study population and samples
The National Ethical Committee approves this cross-
sectional study. Prior to their participation, written in-
formed consent was obtained from all enrolled women.
Participants were collected from Public (National Office
of Family and Population and Department of Gynecology
and Obstetrics) and Private Women’s Healthcare Centers
located at Monastir and Sousse. These locations are two
neighboring coastal towns known for their touristic activ-
ity that share similar lifestyle habits and sociological level.
Inclusion criteria include sexually active (≥1 year) and
non-pregnant women. Exclusion criteria included im-
munocompromised patients, patients under corticosteroid
therapy, hysterectomized women and previous surgical
procedures on the cervix. The cervical sampling was per-
formed according to routine clinical methods and stan-
dards. Trained gynecologist or midwife collected samples
using sterile speculum. A first sample for cytological
screening was collected by the Ayer spatula. Cytological
smears were reported by cytopathologists according to the
2001 Bethesda system. A second sample for molecular
HPV screening was collected by a cytobrush and placed in
5 mL of phosphate buffered saline (PBS).
All subjects were interviewed, during gynecologic visit,
using a questionnaire to collect demographic character-
istics, medical history, contraceptive methods, sexual
and reproductive behavior information and women’s life-
style (age at first intercourse, number of sexual partners,
smoking, alcohol consumption) and knowledge about
HPV screening and vaccine.
HPV-DNA detection
Cervical cells were recovered from the cervical cyto-
brush specimen by centrifugation and viral DNA was ex-
tracted using QIAamp MinElute virus spin kit (Qiagen,
CA, USA) according to the manufacturer’s instructions.
Concentration and purity of the extracted DNA were
evaluated using a NanoDrop spectrophotometer, accord-
ing to the manufacture’s instructions (Thermo Fisher
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Scientific—Nano Drop, USA). To detect HPV-DNA,
real-time polymerase chain reaction (RT-PCR) assay was
performed using MY09/MY11 primers and SYBR Green
I chemistry [23]. Theses primers allow amplification of
highly conserved 450 bp sequence of the L1 gene. To
ensure the DNA quality of the samples, a second primer
pair of PCO3/PCO4 that provides amplification of
100 bp sequence of the β-globin gene was used simultan-
eously as an internal control for each PCR reaction. One
hundred nanograms of the extracted cervical DNA was
added to a mixture containing 12.5 μL of iQ™ SYBR®-
Green Supermix (BioRad, France), 0.64 μM of each pri-
mer MY09/MY11, 0.08 μM of each primer PCO3/PCO4
and nuclease free water yielding a final volume of 25 μL.
The reaction was carried out on an iQ5 thermocycler
(BioRad, France) using the following conditions: initial
denaturation at 94 °C for 5 min followed by 30 cycles of
denaturation at 94 °C for 30 s, annealing primers at 55 °C
for 1 min and primers extension at 72 °C for 90s. A posi-
tive control (cloned HPV-DNA) and a negative control
(nuclease free water) were included in each amplification
reaction. HPV positive samples were detected using dis-
sociation curve, which gave melting peaks at 81 ± 0.5 °C.
For confirmation, PCR products were run on a 2%
agarose gel stained with ethidium bromide and visual-
ized with UV light.
HPV genotyping and variants analysis
HPV-DNA positive samples were subjected to DNA se-
quencing to identify HPV types and HPV-16 variants.
The gel purified L1-PCR products were sequenced using
BigDyeDeoxy terminator cycle sequencing kit (BD V3.1,
Applied Biosystems) according to the manufacturer’s in-
structions. The products were then purified on a separ-
ation column (AutoSeq™ G-50, Amersham Biosciences),
and the templates were sequenced on an automated
ABI-PRISM 310 Genetic Analyzer (Applied Biosystems).
Sequence analysis was performed using nucleotide-
nucleotide BLAST analysis (blastn) against known HPV
genotype and HPV-16 reference variants sequences
stored in the GenBank database (www.ncbi.nlm.nih.gov/
BLAST, June 2015) (Human papillomavirus type 16,
complete genome, GenBank: K02718.1; Human papil-
lomavirus type 16 variant (African type 1), complete
genome, GenBank: AF472508.1; Human papillomavi-
rus type 16 variant (African type 2), complete gen-
ome, GenBank: AF472509.1; Human papillomavirus
type 16 Asian-American variant, complete genome,
GenBank: AF402678.1).
Statistical analysis
Statistical analysis was performed using the SPSS Statis-
tical package (IBM SPSS Statistics version 21.0). The dis-
tribution of age, age at first intercourse and years of
sexual activity, according to the different study popula-
tion subgroups were analyzed and a t-test was used to
compare these quantitative variables. The Chi-square
test was used to estimate the differences in HPV prevalence
between the groups of studied women. The Spearman’s
Rank correlation test was used to test the relationship be-
tween age and age at first intercourse.
A descriptive analysis and frequency distributions were
conducted for all studied risk factors associated with
HPV infection and squamous intraepithelial lesion (SIL)
occurrence (age, age at first intercourse, years of sexual
activity, marital status, number of sexual partners, num-
ber of pregnancies, contraceptive method’s use, meno-
pausal status, Smoking and/or alcohol consumption and
education level) in order to calculate sample size and
percentages. Possible associations between HPV positiv-
ity or SIL and all the above-cited factors were deter-
mined by logistic regression to estimate Odds ratios
(ORs) and 95%-confidence intervals (95%-CIs). Variables
with a p-value less than 0.05 in the univariate analysis
were included in the multivariate analysis. A p-value of
less than 0.05 was considered significant.
Results
Study population characteristics
In this study, no significant difference was observed
when demographic data and distribution of lifestyle fac-
tors of the included women from the different locations
were compared (Monastir and Sousse). Among the 494
eligible women, 23 DNA samples were negative for β-
globin amplification and were consequently excluded
from further analysis. Data were thus evaluated for 471
cases. Demographic, lifestyle and clinical characteristics
of these women were summarized in Table 1. Women
are aged from 17 to 73 years (median, 35 years) and
66.1% are in the age group of 26 to 45 years. The median
age at first intercourse was 22 years (range, 12 to
48 years) and the median period of sexual activity was
12 years (range, 1 to 47 years). To show if there is a
change in sexual behavior over the different generations,
we evaluated using the Spearman’s Rank correlation test
the correlation between age and age at first intercourse.
We found that among younger women (≤40 years), age
at first intercourse was positively correlated with their
age (R = 0.356; p < 10-6). While, among more aged
women (>40 years) a negative correlation was observed
(R = -0.068; p > 0.05). The majority of women have pri-
mary or secondary education (80%); 10% have received
higher education; and 10% were illiterate. The participat-
ing women are mainly non menopausal (90.9%); 16.8%
of them use hormonal contraception and only 1% use
condom as a contraceptive method. Most of the women
are married (76.2%) and 22.3% declared that they have
more than one sexual partner. Vaginal bacterial infections
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were observed among 10% (vaginal candidiasis and tricho-
moniasis). Based on women’s medical files, data about
viral sexually transmitted infections (HSV, HCV and HIV)
were available only for 152 participants and no positive re-
sults were reported. None of the enrolled women have
ever been screened for HPV infection or received HPV
vaccine or heard about the HPV vaccine. Pap smear cy-
tology results show that 15.9% (n = 75) of women have
HPV associated lesions (SIL) and 84.1% (n = 396) of them
have no intraepithelial lesion (NIL). Women with SIL are
classified into 41.3% with low-grade SIL (LSIL) (n = 31)
and 58.7% with high-grade SIL (HSIL) (n = 44).
HPV prevalence
The overall HPV prevalence assessed by real-time
PCR amplification and melting curve analysis was
34% (n = 160, 95% CI: 30–38%) with significantly
higher prevalence among women with SIL than those with
NIL 84% (n = 63, 95% CI: 76–92%) and 24.5% (n = 97, 95%
CI: 20–29%) respectively, p < 10-6) (Table 2). Furthermore,
the HR-HPV prevalence was four times higher among
women with SIL than women with NIL. HPV prevalence
was not significant between women with LSIL and HSIL
(87.1%, 95% CI: 75–100% and 81.8%, 95% CI: 70–94%, re-
spectively). However, HR-HPV prevalence rate was about
two times higher among women with HSIL compared to
women with LSIL (70%, 95% CI: 55–85%, and 42.3%,
95% CI: 22–63%, respectively, p = 0. 025). Moreover,
as expected, NIL women having multiple sexual partners
had a significantly higher HPV prevalence than NIL
women having one sexual partner (42.4% (n = 42, 95% CI:
33–52%) and 18.5% (n = 55, 95% CI: 14–23%) respectively,
p = 3.10-5). The HR-HPV prevalence rate was about three
times higher among women who have multiple sexual
partners than those who have one sexual partner
(31.5%, 95% CI: 22–41% and 9.4%, 95% CI: 6–13%,
respectively, p < 10-6).
We then analyzed the prevalence of HPV infection ac-
cording to the age groups of women (Fig. 1). The distri-
bution of HPV prevalence, showed a U-shaped curve
with peaks of HPV prevalence among the youngest
women (≤25 years; 51.2%, 95% CI: 37–67%) and the oldest
women (>55 years; 41.7%, 95% CI: 20–63%). The lowest
HPV prevalence was observed among women aged from
36 to 45 years (17.2%, 95% CI: 10–24%). Moreover, the
distribution of HR-HPV prevalence according to age
groups shows the same pattern as overall HPV preva-
lence (Fig. 1). Highest HR-HPV prevalence rates were
observed among the youngest aged women (≤25 years;
34.9%, 95% CI: 20–50%), and among the oldest aged
women (>55 years; 34.8%, 95% CI: 14–56%).
HPV genotype and HPV-16 variants distribution
HPV-DNA positive samples were analyzed by direct se-
quencing to identify HPV genotype distribution in the
study population. Out of the 160 samples positive for
HPV infection, 35 samples were lacking in HPV geno-
typing because of the poor quality of the cervical DNA.
As shown in Table 3, 18 different HPV types were iden-
tified in our population and five cases of co-infections
Table 1 Epidemiologic and lifestyle characteristics of the study
population
Characteristic Total
n = 471 (%)
Age (years)




≥ 56 28 (5.9)
Age at first intercourse (years)
< 20 123 (26.1)
20–24 213 (45.2)
≥ 25 135 (28.7)
Years of sexual activity
≤ 10 200 (42.5)
11–20 149 (31.6)











Non hormonal 74 (15.7)
Menopausal status
Non menopausal 424 (90.9)
Menopausal 47 (9.1)
Number of sexual partner
1 366 (77.7)
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were also observed. Among the 125 HPV-positive sam-
ples analyzed, HPV-16 was the most frequent genotype,
accounting for 44.8%, (n = 56, 95% CI: 20–29%) followed
by HPV-6 (11.2%, 95% CI: 6–17%), HPV-11 (7.2%, 95%
CI: 3–12%), HPV-31 (5.6%, 95% CI: 2–10%), HPV-58
(5.6%, 95% CI: 2–10%) and HPV-66 (4.8%, 95% CI: 1–9%).
However, HPV-18 prevalence rate was less than 2% (95%
CI: 0–4%). Among the nine HR-HPV types detected,
HPV-45 was the least frequent type, which was detected
in only one case of HSIL. HR HPV types were more
prevalent among HPV positive women having multiple
sexual partners and HSIL (23.2%, 95% CI: 16–31%, and
22.4%, 95% CI: 15–30%, respectively). HPV-16 was the
most prevalent HR type among women with NIL and SIL
(9.2%, 95% CI: 6–12% and 32.8%, 95% CI: 22–45%, re-
spectively), it was also frequent among women having
multiple sexual partners and HSIL (12.1%, 95% CI: 5–19%
and 43.9%, 95% CI: 29–61%, respectively). Concerning
LR-HPV types, they were more frequent among LSIL
women (42.3%, 95% CI: 22–63%) (Table 3).
In the current study, molecular characterization of
HPV-16 variants was performed using MY09/MY11-L1
region. Three different HPV-16 variants, European (E),
African-2 (Af-2) and Asian-American (AA), were detected
in our population study. None of the HPV-16 positive
cases belongs to African-1 variant. HPV-16 E variant
was the most frequent (85.7%, 95% CI: 76–95%). The
prevalence of the HPV-16 E variant was highest in
HSIL (34.2%, 95% CI: 20–50%), followed by LSIL
(15.4%, 95% CI: 1–30%), NIL (8.13%, 95% CI: 5–11%).
The majority of HPV-16 Af-2 variant was found in
HSIL than NIL (9.8%, 95% CI: 0–20%), 0.5%, 95% CI:
0–1%, respectively). The HPV-16 AA variant was detected
only among women with NIL (0.5%, 95% CI: 0–1%).
Risk Factors for HPV infection
In univariate analysis, the association between HPV in-
fection and several risk factors among our study popula-
tion were assessed (Table 4). The results showed that,
HPV and HR-HPV infection was significantly associated
with women’s lifestyle (marital status, number of sexual
partners and smoking/alcohol consumption) and young
age. However, other risk factors such as age at first inter-
course, number of pregnancies, contraceptive methods,
menopausal status and education level were not associ-
ated with HPV or HR-HPV infection. The risk factors
with a p-value less than 0.05 from univariate analysis
were further included in multivariate analysis (Table 4).
These results showed that, only young (<30 years) age
was an independent factor associated with HPV infec-
tion. Moreover, it significantly increases the risk of HR-
HPV infection. Number of sexual partners was not
found to be an independent risk factor for HPV and HR-
HPV infections in our study population.
Risk Factors for SIL occurrence
When we compared epidemiological, demographic, and
lifestyle habits of women with NIL and SIL, we found
that women with SIL had a higher HPV prevalence, a
younger age at first intercourse and a longer period of
sexual activity (p < 10-6, p = 0.008 and p = 0.010, respect-
ively). In addition, when we compared characteristics of
LSIL women with HSIL women, we found that those
with HSIL had a significantly higher HR-HPV preva-
lence, were older and had a longer period of sexual
Table 2 HPV prevalence among women with normal cytology and squamous intraepithelial lesion













HPV positive women 97 63 27 36
HPV prevalence (%) 24.5 84 87.1 81.8 0.541 <10-6
1.5 [0.409–5.503] 16.183 [8.377–31.262]
HR-HPV positive women 55 39 11 28
HR-HPV prevalence (%) 14.9 59.1 42.3 70 0.025 <10-6
3.181[1.135–8.920] 8.273 [4.687–14.602]
LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; p, results of LSIL vs HSIL comparison; p’, results of NIL vs
SIL comparison
Fig. 1 Distribution of age specific HPV and HR-HPV prevalence and
their corresponding 95% confidence interval (CI)
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activity (p = 0.025, p = 0.004 and p = 0.010, respectively).
No more significant differences were found between
women with NIL and SIL or between HSIL and LSIL.
Furthermore, we conducted univariate and multivari-
ate analysis to determine the association between risk of
SIL or HSIL occurrence and different putative risk fac-
tors (Table 5). The univariate analysis results show that,
as expected, HPV infection was the main significant as-
sociated risk factor, together with menopause for SIL.
However, no statistically significant associations were
observed with women’s age, age at first intercourse,
period of sexual activity, the number of pregnancies,
contraceptive methods, smoking/alcohol consumption
and education level. In univariate analysis, we found sig-
nificant association between HSIL and HPV infection,
period of sexual activity longer than 10 years and meno-
pause. While, in multivariate analysis, HPV infection,
and menopause were independent risk factors for both
SIL and HSIL (Table 5).
Discussion
Since the commercialization of preventive HPV vaccines
introduced in 2006, limited studies have been performed
on molecular epidemiology of HPV infection among
Tunisian women. The first molecular studies pub-
lished results on the HPV infection among women
with normal cervical cytology having different lifestyle
practices [20, 21]. Recently, HPV type and variants
distribution have been assessed in cervical tumor tis-
sues from Tunisian patients [24]. However, there are
insufficient data on the risk factors for HPV infection
and cervical intraepithelial lesions. Tunisia is the only
country in the Arab Muslim ones where polygamy is
forbidden by law since 1956 and where the minimum
Table 3 HPV genotypes distribution among women with normal cytology and squamous intraepithelial lesion
HPV type Whole HPV No Intraepithelial Lesion Squamous Intraepithelial Lesion
Total Total LSIL HSIL
HR-HPV 85 48 37 11 26
HPV-16 56 34 22 4 18
HPV-18 2 1 1 0 1
HPV-31 7 3 4 3 1
HPV-33 3 1 2 0 2
HPV-45 1 0 1 0 1
HPV-56 4 0 4 3 1
HPV-58 7 4 3 1 2
HPV-68 3 3 0 0 0
HPV-82 2 2 0 0 0
Probably HR-HPV 9 7 2 0 2
HPV-53 3 3 0 0 0
HPV-66 6 4 2 0 2
LR-HPV 31 16 15 11 4
HPV-6 14 5 9 5 4
HPV-11 9 3 6 6 0
HPV-61 1 1 0 0 0
HPV-70 1 1 0 0 0
HPV-81 1 1 0 0 0
HPV-83 1 1 0 0 0
HPV-84 4 4 0 0 0
Co-infection 5 2 3 2 1
HPV-6/11 2 1 1 1 0
HPV-11/18 1 1 0 0 0
HPV-11/31 1 0 1 1 0
HPV-16/18 1 0 1 0 1
LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion
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legal age of marriage for females is the highest
(18 years) in the Extended Middle East and North
Africa (EMENA) region. Moreover, the male circumcision
is a generalized practice among Muslim countries includ-
ing Tunisia [25]. All these reasons could contribute to the
reduced risk of HPV associated lesions among Tunisian
women. Furthermore, Tunisia had a peculiar relation-
ship with Mediterranean Europe where populations
are less conservative (colonization and immigration).
Thus, Tunisia is a North-African country with distinctive
characteristics from other North-African, Middle Eastern
and Sub-Saharian countries, where epidemiological stud-
ies to identify risk factors should be investigated to help
the establishment of a routinely HPV testing and a vaccin-
ation program.
In this study, 15.9% of the enrolled women have
squamous intraepithelial lesions and the HPV preva-
lence among them was 84%. This rate is comparable
to those reported worldwide [26]. Few studies were
conducted on HPV testing in the EMENA region,
and results show that HPV prevalence in precancer-
ous cervical lesions is ranged from 15% to 100% [27].
The differences in HPV prevalence among women
with cervical lesions between the studies of the
EMENA region are more likely due to the use of
HPV testing methods with different sensitivity (ISH,
Table 4 Univariate and multivariate logistic regression analysis of risk factors for HPV infection
Risk Factors Risks for HPV infection
(n = 471)
Risks for HR-HPV infection
(n = 436)a
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HPV prevalence (%) p OR [95% CI] HR-HPV prevalence (%) p’ OR [95% CI]
Age
≤ 30 41.1 1 24.8 1
> 30 26.4 0.002 0.51 [0.33–0.79] 16 0.041 0.57 [0.34–0.98]
Marital status
Married 28.8 16.6
Unmarried 41.7 0.012 ns 31.7 0.001 ns
Number of sexual partners
1 28.5 16.5
≥ 2 43.6 0.004 ns 33 4.10-4 ns
Smoking/alcohol consumption
No 23.7 14.5
Yes 46.8 4.10-5 ns 36 1.10-5 ns
ns, not significant; p, probability for HPV infection; p’, probability for HR-HPV infection
astudy population without samples lacking in HPV genotyping (n = 35)
Table 5 Univariate and multivariate logistic regression analysis of risk factors for squamous intraepithelial lesion and high-grade
squamous intraepithelial lesion




Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
SIL (%) P OR [95% CI] HSIL (%) P’ OR [95% CI]
HPV status
HPV negative 3.9 1 2.6 1
HPV positive 39.4 <10-6 14.10 [7.00–28.40] 22.5 <10-6 11.06 [4.61–26.56]
Years of sexual activity
≤ 10 10.3 4.8
> 10 16.5 0.080 ni 11.6 0.020 ns
Menopausal status
Non menopausal 12 1 6 1
Menopausal 34.1 6.10-5 3.66 [1.62–8.29] 31.8 <10-6 7.30 [3.11–17.13]
n, number; ns, not significant; ni, not included in the multivariate analysis; SIL, squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; p,
probability for SIL; p’, probability for HSIL
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FISH, PCR, hybrid capture methods) and small sam-
ple size [27–29].
For women without cervical lesions, the HPV preva-
lence was 24.5%, and as expected prevalence was found
to be significantly higher among those having multiple
sexual partners (42.4%) compared to those having one
sexual partner (18.5%) or married (19.2%). Previously,
Hassen et al., published HPV prevalence in women with
normal cervical cytology from the central region of
Tunisia (Sousse and Monastir) [20]. They observed a
higher HPV prevalence in prostitutes (39%) compared to
married women (14%) [20]. Herein, the slight increase in
HPV prevalence among married women could be due to
the use of the q-PCR method, which is more sensitive
than the conventional PCR used previously by Hassen et
al., rather than the change in the lifestyle and sexual
habits in both Tunisian men and women. However, be-
cause of the cultural traditions, the limitation of this
study is the lack of data about the sexual partner, extra-
marital relationships (for wives and husbands), sexual
life and practice that are still taboo subjects. Considering
women with normal cervical cytology, when we com-
pared the overall HPV prevalence among Tunisian
women with that from neighboring Northern African
countries, we reported that it was higher than that of
Algeria (5.3%) [22], but lower than that of Morocco
(34.3%) [30]. Additionally, we found relatively high HPV
prevalence compared to Arab-Muslim countries from
the Middle-East [31–33] but substantially lower than
that reported by other studies of the Sub-Saharan coun-
tries [34, 35] and Mediterranean Europe [36, 37]. The
different origins and characteristics of the studied popu-
lation (age, lifestyle, and ethnicity) may be the reason of
these disparities in HPV prevalence.
In our study, eighteen different HPV types were de-
tected. Out of the eleven oncogenic types, HPV-16
was the most common in our population and six
(HPV-16, -18, -31, -33, -58, and -66) were found
among NIL, which was consistent with global studies
in women with normal cervical cytology [38]. Among
women with HSIL, the predominant genotype HPV-
16 was followed by HPV-33, -58 and -66. However, in
this group, HPV-18 was detected only in one case of
co-infection with HPV-16. To the best of our know-
ledge, this is the first study, which describes HPV-16
variants distribution among Tunisian women with and
without cervical intraepithelial lesions. The distribu-
tion of major variants around the world was known
to be highly geographically and ethnically specific. For
instance, the European variant is known to be spread
worldwide, except for Sub-Saharan Africa, where the
African variants are more prevalent [39]. In our co-
hort, HPV-16 European variant was the most com-
mon (85.7%), this may be due to the geographical
location and historical links between Tunisia and the
European continent. Our results showed that the rate
of HPV-16 E variant was higher among NIL women
than SIL women (88.2% and 81.8%, respectively)
whereas, non-European variants were high among SIL
women compared to NIL women (18% and 12%, re-
spectively). KrennHrubec et al., observed that among
cervical cancer cases collected from the center of
Tunisia, a prevalence rate was of 61% for the HPV-16
E variant and of 40% for the non-European variants
[24]. Non-European variants were also reported to be
frequently observed among cervical cancer cases from
Morocco [40]. Altogether, these results suggest that
the prevalence of non-European variants increases with
the severity of the lesion. The relationship between non-
European lineage and occurrence of cervical lesions in
Tunisian women should be more investigated.
We also explored risk factors influencing HPV infec-
tion and squamous intraepithelial lesions occurrence.
Previous studies have shown that young age, age at the
first sexual intercourse, multiple sexual partners, oral
contraceptive use, smoking, number of pregnancies and
menopause are the specific risk factors for cervical HPV
infection [41–46]. In our study, multivariate analysis
showed that only young age is independently associated
with HPV infection. Moreover, numerous factors have
been assessed for a putative link with SIL. This study is
the first that reported risk factors for SIL occurrence for
Tunisian women. Women are at increased risk of SIL
and HSIL if they have HPV infection or are in meno-
pause. The latter observation may be related to the com-
bined effect of the persistence or the reactivation of
HPV infection with weakness of the local immune re-
sponse at menopause. Accordingly, Castle et al, demon-
strated that HPV persistence increased significantly for
post-menopausal women [47]. Hormonal disturbance of
the menopause was associated with deregulated immune
function; for instance the decrease of estrogen level in-
duces a poor ability to eliminate HPV infection [48, 49].
Herein, women with SIL are older and have a younger
age at first intercourse than women with NIL. Recent
studies reported that both, adolescents with immature
epithelium and menopausal women have an affected ex-
pression of inflammatory cytokines and chemokines in
cervical samples [50, 51]. Altogether, these observations
may explain the age-related HPV prevalence pattern for
young and menopausal women. Thus, adding HPV
testing to Pap smear screening for menopausal
women may improve the detection of a persistent or
a recent HPV infection.
Evaluation of prevalence and genotype distribution of
HPV infection in the general population is very import-
ant to estimate the potential impact of current HPV vac-
cines. Currently, three vaccines against HPV infection
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are available and distributed in more than 100 coun-
tries (a bivalent to prevent HPV-16 and HPV-18 in-
fection, a quadrivalent to prevent HPV-16, -18, -6
and -11 infection and a nonavalent HPV vaccine target-
ing HPV-16, -18, -31, -33, -45, -52, -58, -6, and -11). How-
ever, HPV type classification shows a great difference
between geographic regions worldwide [52, 53]. HPV bi-
valent vaccine is commercially available in Tunisia, but
none of the women included in this study heard about it.
Our study shows that HPV types targeted by the bivalent
vaccine were found among 13% of the women. Thus, in
Tunisia, there is a need to establish advertisement and
public campaigns for HPV vaccine and to consider the
quadrivalent and nonavalent HPV vaccines as alternatives
to the bivalent vaccine.
Conclusion
This cross-sectional study contributes to the knowledge
of HPV epidemiology in Tunisian women with and with-
out cervical lesions. We found that infected menopausal
women were at higher risk to develop cervical lesions.
We also found that the HPV-16 was dominant and that
the HPV-18 was not very common, suggesting that the
currently available bivalent vaccine may have lower effi-
ciency with Tunisian women. Altogether, these results
may be helpful for designing an adapted HPV testing
and vaccination program in Tunisia.
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